Sen. Chapin Rose

Filed: 3/1/2017

 

 


 

 


 
10000SB2038sam001LRB100 11368 MJP 22277 a

1
AMENDMENT TO SENATE BILL 2038

2    AMENDMENT NO. ______. Amend Senate Bill 2038 by replacing
3everything after the enacting clause with the following:
 
4    "Section 1. Short title. This Act may be cited as the
5Epinephrine Administration Act.
 
6    Section 5. Definitions. As used in this Act:
7    "Authorized entity" means any entity or organization,
8other than a school covered under Section 22-30 of the School
9Code, in connection with or at which allergens capable of
10causing anaphylaxis may be present, including, but not limited
11to, independent contractors who provide student transportation
12to schools, recreation camps, colleges and universities, day
13care facilities, youth sports leagues, amusement parks,
14restaurants, sports arenas, and places of employment. The
15Department shall, by rule, determine what constitutes a day
16care facility under this definition.

 

 

10000SB2038sam001- 2 -LRB100 11368 MJP 22277 a

1    "Department" means the Department of Public Health.
2    "Epinephrine glass vial, ampule, or pre-filled syringe"
3means a glass vial of epinephrine, ampule of epinephrine, or
4pre-filled syringe of epinephrine used for the administration
5of a pre-measured dose of epinephrine into the human body.
6    "Health care practitioner" means a physician licensed to
7practice medicine in all its branches under the Medical
8Practice Act of 1987, a physician assistant under the Physician
9Assistant Practice Act of 1987 with prescriptive authority, or
10an advanced practice nurse with prescribing authority under
11Article 65 of the Nurse Practice Act.
12    "Pharmacist" has the meaning given to that term under
13subsection (k-5) of Section 3 of the Pharmacy Practice Act.
14    "Undesignated epinephrine glass vial, ampule, or
15pre-filled syringe" means an epinephrine glass vial, ampule, or
16pre-filled syringe prescribed in the name of an authorized
17entity.
 
18    Section 10. Prescription to authorized entity; use;
19training.
20    (a) A health care practitioner may prescribe epinephrine
21glass vials, ampules, or pre-filled syringes in the name of an
22authorized entity for use in accordance with this Act, and
23pharmacists and health care practitioners may dispense
24epinephrine glass vials, ampules, or pre-filled syringes
25pursuant to a prescription issued in the name of an authorized

 

 

10000SB2038sam001- 3 -LRB100 11368 MJP 22277 a

1entity. Such prescriptions shall be valid for a period of 2
2years.
3    (b) An authorized entity may acquire and stock a supply of
4undesignated epinephrine glass vials, ampules, or pre-filled
5syringes pursuant to a prescription issued under subsection (a)
6of this Section. Such undesignated epinephrine glass vials,
7ampules, or pre-filled syringes shall be stored in a location
8readily accessible in an emergency and in accordance with the
9instructions for use of the epinephrine glass vials, ampules,
10or pre-filled syringes. The Department may establish any
11additional requirements an authorized entity must follow under
12this Act.
13    (c) An employee or agent of an authorized entity or other
14individual who has completed training under subsection (d) of
15this Section may:
16        (1) provide an epinephrine glass vial, ampule, or
17    pre-filled syringe to any individual on the property of the
18    authorized entity whom the employee, agent, or other
19    individual believes in good faith is experiencing
20    anaphylaxis, or to the parent, guardian, or caregiver of
21    such individual, for immediate administration, regardless
22    of whether the individual has a prescription for an
23    epinephrine glass vial, ampule, or pre-filled syringe or
24    has previously been diagnosed with an allergy; or
25        (2) administer epinephrine from a glass vial, ampule,
26    or pre-filled syringe to any individual on the property of

 

 

10000SB2038sam001- 4 -LRB100 11368 MJP 22277 a

1    the authorized entity whom the employee, agent, or other
2    individual believes in good faith is experiencing
3    anaphylaxis, regardless of whether the individual has a
4    prescription for an epinephrine glass vial, ampule, or
5    pre-filled syringe or has previously been diagnosed with an
6    allergy.
7    (d) An employee, agent, or other individual authorized must
8complete an anaphylaxis training program before he or she is
9able to provide or administer epinephrine from a glass vial,
10ampule, or pre-filled syringe under this Section. Such training
11shall be valid for a period of 2 years and shall be conducted
12by a nationally recognized organization experienced in
13training laypersons in emergency health treatment. The
14Department shall include links to training providers' websites
15on its website.
16    Training shall include, but is not limited to:
17        (1) how to recognize signs and symptoms of an allergic
18    reaction, including anaphylaxis;
19        (2) how to administer epinephrine from a glass vial,
20    ampule, or pre-filled syringe; and
21        (3) a test demonstrating competency of the knowledge
22    required to recognize anaphylaxis and administer
23    epinephrine from a glass vial, ampule, or pre-filled
24    syringe.
25    Training may also include, but is not limited to:
26        (A) a review of high-risk areas on the authorized

 

 

10000SB2038sam001- 5 -LRB100 11368 MJP 22277 a

1    entity's property and its related facilities;
2        (B) steps to take to prevent exposure to allergens;
3        (C) emergency follow-up procedures; and
4        (D) other criteria as determined in rules adopted
5    pursuant to this Act.
6    Training may be conducted either online or in person. The
7Department shall approve training programs and list permitted
8training programs on the Department's Internet website.
 
9    Section 15. Costs. Whichever entity initiates the process
10of obtaining undesignated epinephrine glass vials, ampules, or
11pre-filled syringes and providing training to personnel for
12carrying and administering epinephrine from undesignated
13epinephrine glass vials, ampules, or pre-filled syringes shall
14pay for the costs of the undesignated epinephrine glass vials,
15ampules, or pre-filled syringes.
 
16    Section 20. Limitations. The use of an undesignated
17epinephrine glass vial, ampule, or pre-filled syringe in
18accordance with the requirements of this Act does not
19constitute the practice of medicine or any other profession
20that requires medical licensure.
21    Nothing in this Act shall limit the amount of epinephrine
22glass vials, ampules, or pre-filled syringes that an authorized
23entity or individual may carry or maintain a supply of.
 

 

 

10000SB2038sam001- 6 -LRB100 11368 MJP 22277 a

1    Section 85. Rulemaking. The Department shall adopt any
2rules necessary to implement and administer this Act.
 
3    Section 90. The School Code is amended by changing Section
422-30 as follows:
 
5    (105 ILCS 5/22-30)
6    Sec. 22-30. Self-administration and self-carry of asthma
7medication and epinephrine injectors auto-injectors;
8administration of undesignated epinephrine injectors
9auto-injectors; administration of an opioid antagonist; asthma
10episode emergency response protocol.
11    (a) For the purpose of this Section only, the following
12terms shall have the meanings set forth below:
13    "Asthma action plan" means a written plan developed with a
14pupil's medical provider to help control the pupil's asthma.
15The goal of an asthma action plan is to reduce or prevent
16flare-ups and emergency department visits through day-to-day
17management and to serve as a student-specific document to be
18referenced in the event of an asthma episode.
19    "Asthma episode emergency response protocol" means a
20procedure to provide assistance to a pupil experiencing
21symptoms of wheezing, coughing, shortness of breath, chest
22tightness, or breathing difficulty.
23    "Asthma inhaler" means a quick reliever asthma inhaler.
24    "Epinephrine auto-injector" means a single-use device used

 

 

10000SB2038sam001- 7 -LRB100 11368 MJP 22277 a

1for the automatic injection of a pre-measured dose of
2epinephrine into the human body.
3    "Epinephrine injector" includes a glass vial,
4auto-injector, ampule, or pre-filled syringe used for the
5administration of epinephrine.
6    "Asthma medication" means a medicine, prescribed by (i) a
7physician licensed to practice medicine in all its branches,
8(ii) a licensed physician assistant with prescriptive
9authority, or (iii) a licensed advanced practice nurse with
10prescriptive authority for a pupil that pertains to the pupil's
11asthma and that has an individual prescription label.
12    "Opioid antagonist" means a drug that binds to opioid
13receptors and blocks or inhibits the effect of opioids acting
14on those receptors, including, but not limited to, naloxone
15hydrochloride or any other similarly acting drug approved by
16the U.S. Food and Drug Administration.
17    "School nurse" means a registered nurse working in a school
18with or without licensure endorsed in school nursing.
19    "Self-administration" means a pupil's discretionary use of
20his or her prescribed asthma medication or epinephrine injector
21auto-injector.
22    "Self-carry" means a pupil's ability to carry his or her
23prescribed asthma medication or epinephrine injector
24auto-injector.
25    "Standing protocol" may be issued by (i) a physician
26licensed to practice medicine in all its branches, (ii) a

 

 

10000SB2038sam001- 8 -LRB100 11368 MJP 22277 a

1licensed physician assistant with prescriptive authority, or
2(iii) a licensed advanced practice nurse with prescriptive
3authority.
4    "Trained personnel" means any school employee or volunteer
5personnel authorized in Sections 10-22.34, 10-22.34a, and
610-22.34b of this Code who has completed training under
7subsection (g) of this Section to recognize and respond to
8anaphylaxis.
9    "Undesignated epinephrine injector auto-injector" means an
10epinephrine injector auto-injector prescribed in the name of a
11school district, public school, or nonpublic school.
12    (b) A school, whether public or nonpublic, must permit the
13self-administration and self-carry of asthma medication by a
14pupil with asthma or the self-administration and self-carry of
15an epinephrine injector auto-injector by a pupil, provided
16that:
17        (1) the parents or guardians of the pupil provide to
18    the school (i) written authorization from the parents or
19    guardians for (A) the self-administration and self-carry
20    of asthma medication or (B) the self-carry of asthma
21    medication or (ii) for (A) the self-administration and
22    self-carry of an epinephrine injector auto-injector or (B)
23    the self-carry of an epinephrine injector auto-injector,
24    written authorization from the pupil's physician,
25    physician assistant, or advanced practice nurse; and
26        (2) the parents or guardians of the pupil provide to

 

 

10000SB2038sam001- 9 -LRB100 11368 MJP 22277 a

1    the school (i) the prescription label, which must contain
2    the name of the asthma medication, the prescribed dosage,
3    and the time at which or circumstances under which the
4    asthma medication is to be administered, or (ii) for the
5    self-administration or self-carry of an epinephrine
6    injector auto-injector, a written statement from the
7    pupil's physician, physician assistant, or advanced
8    practice nurse containing the following information:
9            (A) the name and purpose of the epinephrine
10        injector auto-injector;
11            (B) the prescribed dosage; and
12            (C) the time or times at which or the special
13        circumstances under which the epinephrine injector
14        auto-injector is to be administered.
15The information provided shall be kept on file in the office of
16the school nurse or, in the absence of a school nurse, the
17school's administrator.
18    (b-5) A school district, public school, or nonpublic school
19may authorize the provision of a student-specific or
20undesignated epinephrine injector auto-injector to a student
21or any personnel authorized under a student's Individual Health
22Care Action Plan, Illinois Food Allergy Emergency Action Plan
23and Treatment Authorization Form, or plan pursuant to Section
24504 of the federal Rehabilitation Act of 1973 to administer an
25epinephrine injector auto-injector to the student, that meets
26the student's prescription on file.

 

 

10000SB2038sam001- 10 -LRB100 11368 MJP 22277 a

1    (b-10) The school district, public school, or nonpublic
2school may authorize a school nurse or trained personnel to do
3the following: (i) provide an undesignated epinephrine
4injector auto-injector to a student for self-administration
5only or any personnel authorized under a student's Individual
6Health Care Action Plan, Illinois Food Allergy Emergency Action
7Plan and Treatment Authorization Form, or plan pursuant to
8Section 504 of the federal Rehabilitation Act of 1973 to
9administer to the student, that meets the student's
10prescription on file; (ii) administer an undesignated
11epinephrine injector auto-injector that meets the prescription
12on file to any student who has an Individual Health Care Action
13Plan, Illinois Food Allergy Emergency Action Plan and Treatment
14Authorization Form, or plan pursuant to Section 504 of the
15federal Rehabilitation Act of 1973 that authorizes the use of
16an epinephrine injector auto-injector; (iii) administer an
17undesignated epinephrine injector auto-injector to any person
18that the school nurse or trained personnel in good faith
19believes is having an anaphylactic reaction; and (iv)
20administer an opioid antagonist to any person that the school
21nurse or trained personnel in good faith believes is having an
22opioid overdose.
23    (c) The school district, public school, or nonpublic school
24must inform the parents or guardians of the pupil, in writing,
25that the school district, public school, or nonpublic school
26and its employees and agents, including a physician, physician

 

 

10000SB2038sam001- 11 -LRB100 11368 MJP 22277 a

1assistant, or advanced practice nurse providing standing
2protocol or prescription for school epinephrine injectors
3auto-injectors, are to incur no liability or professional
4discipline, except for willful and wanton conduct, as a result
5of any injury arising from the administration of asthma
6medication, an epinephrine injector auto-injector, or an
7opioid antagonist regardless of whether authorization was
8given by the pupil's parents or guardians or by the pupil's
9physician, physician assistant, or advanced practice nurse.
10The parents or guardians of the pupil must sign a statement
11acknowledging that the school district, public school, or
12nonpublic school and its employees and agents are to incur no
13liability, except for willful and wanton conduct, as a result
14of any injury arising from the administration of asthma
15medication, an epinephrine injector auto-injector, or an
16opioid antagonist regardless of whether authorization was
17given by the pupil's parents or guardians or by the pupil's
18physician, physician assistant, or advanced practice nurse and
19that the parents or guardians must indemnify and hold harmless
20the school district, public school, or nonpublic school and its
21employees and agents against any claims, except a claim based
22on willful and wanton conduct, arising out of the
23administration of asthma medication, an epinephrine injector
24auto-injector, or an opioid antagonist regardless of whether
25authorization was given by the pupil's parents or guardians or
26by the pupil's physician, physician assistant, or advanced

 

 

10000SB2038sam001- 12 -LRB100 11368 MJP 22277 a

1practice nurse.
2    (c-5) When a school nurse or trained personnel administers
3an undesignated epinephrine injector auto-injector to a person
4whom the school nurse or trained personnel in good faith
5believes is having an anaphylactic reaction or administers an
6opioid antagonist to a person whom the school nurse or trained
7personnel in good faith believes is having an opioid overdose,
8notwithstanding the lack of notice to the parents or guardians
9of the pupil or the absence of the parents or guardians signed
10statement acknowledging no liability, except for willful and
11wanton conduct, the school district, public school, or
12nonpublic school and its employees and agents, and a physician,
13a physician assistant, or an advanced practice nurse providing
14standing protocol or prescription for undesignated epinephrine
15injectors auto-injectors, are to incur no liability or
16professional discipline, except for willful and wanton
17conduct, as a result of any injury arising from the use of an
18undesignated epinephrine injector auto-injector or the use of
19an opioid antagonist regardless of whether authorization was
20given by the pupil's parents or guardians or by the pupil's
21physician, physician assistant, or advanced practice nurse.
22    (d) The permission for self-administration and self-carry
23of asthma medication or the self-administration and self-carry
24of an epinephrine injector auto-injector is effective for the
25school year for which it is granted and shall be renewed each
26subsequent school year upon fulfillment of the requirements of

 

 

10000SB2038sam001- 13 -LRB100 11368 MJP 22277 a

1this Section.
2    (e) Provided that the requirements of this Section are
3fulfilled, a pupil with asthma may self-administer and
4self-carry his or her asthma medication or a pupil may
5self-administer and self-carry an epinephrine injector
6auto-injector (i) while in school, (ii) while at a
7school-sponsored activity, (iii) while under the supervision
8of school personnel, or (iv) before or after normal school
9activities, such as while in before-school or after-school care
10on school-operated property or while being transported on a
11school bus.
12    (e-5) Provided that the requirements of this Section are
13fulfilled, a school nurse or trained personnel may administer
14an undesignated epinephrine injector auto-injector to any
15person whom the school nurse or trained personnel in good faith
16believes to be having an anaphylactic reaction (i) while in
17school, (ii) while at a school-sponsored activity, (iii) while
18under the supervision of school personnel, or (iv) before or
19after normal school activities, such as while in before-school
20or after-school care on school-operated property or while being
21transported on a school bus. A school nurse or trained
22personnel may carry undesignated epinephrine injectors
23auto-injectors on his or her person while in school or at a
24school-sponsored activity.
25    (e-10) Provided that the requirements of this Section are
26fulfilled, a school nurse or trained personnel may administer

 

 

10000SB2038sam001- 14 -LRB100 11368 MJP 22277 a

1an opioid antagonist to any person whom the school nurse or
2trained personnel in good faith believes to be having an opioid
3overdose (i) while in school, (ii) while at a school-sponsored
4activity, (iii) while under the supervision of school
5personnel, or (iv) before or after normal school activities,
6such as while in before-school or after-school care on
7school-operated property. A school nurse or trained personnel
8may carry an opioid antagonist on their person while in school
9or at a school-sponsored activity.
10    (f) The school district, public school, or nonpublic school
11may maintain a supply of undesignated epinephrine injectors
12auto-injectors in any secure location that is accessible
13before, during, and after school where an allergic person is
14most at risk, including, but not limited to, classrooms and
15lunchrooms. A physician, a physician assistant who has been
16delegated prescriptive authority in accordance with Section
177.5 of the Physician Assistant Practice Act of 1987, or an
18advanced practice nurse who has been delegated prescriptive
19authority in accordance with Section 65-40 of the Nurse
20Practice Act may prescribe undesignated epinephrine injectors
21auto-injectors in the name of the school district, public
22school, or nonpublic school to be maintained for use when
23necessary. Any supply of epinephrine injectors auto-injectors
24shall be maintained in accordance with the manufacturer's
25instructions.
26    The school district, public school, or nonpublic school may

 

 

10000SB2038sam001- 15 -LRB100 11368 MJP 22277 a

1maintain a supply of an opioid antagonist in any secure
2location where an individual may have an opioid overdose. A
3health care professional who has been delegated prescriptive
4authority for opioid antagonists in accordance with Section
55-23 of the Alcoholism and Other Drug Abuse and Dependency Act
6may prescribe opioid antagonists in the name of the school
7district, public school, or nonpublic school, to be maintained
8for use when necessary. Any supply of opioid antagonists shall
9be maintained in accordance with the manufacturer's
10instructions.
11    (f-3) Whichever entity initiates the process of obtaining
12undesignated epinephrine injectors auto-injectors and
13providing training to personnel for carrying and administering
14undesignated epinephrine injectors auto-injectors shall pay
15for the costs of the undesignated epinephrine injectors
16auto-injectors.
17    (f-5) Upon any administration of an epinephrine injector
18auto-injector, a school district, public school, or nonpublic
19school must immediately activate the EMS system and notify the
20student's parent, guardian, or emergency contact, if known.
21    Upon any administration of an opioid antagonist, a school
22district, public school, or nonpublic school must immediately
23activate the EMS system and notify the student's parent,
24guardian, or emergency contact, if known.
25    (f-10) Within 24 hours of the administration of an
26undesignated epinephrine injector auto-injector, a school

 

 

10000SB2038sam001- 16 -LRB100 11368 MJP 22277 a

1district, public school, or nonpublic school must notify the
2physician, physician assistant, or advanced practice nurse who
3provided the standing protocol or prescription for the
4undesignated epinephrine injector auto-injector of its use.
5    Within 24 hours after the administration of an opioid
6antagonist, a school district, public school, or nonpublic
7school must notify the health care professional who provided
8the prescription for the opioid antagonist of its use.
9    (g) Prior to the administration of an undesignated
10epinephrine injector auto-injector, trained personnel must
11submit to their school's administration proof of completion of
12a training curriculum to recognize and respond to anaphylaxis
13that meets the requirements of subsection (h) of this Section.
14Training must be completed annually. their The school district,
15public school, or nonpublic school must maintain records
16related to the training curriculum and trained personnel.
17    Prior to the administration of an opioid antagonist,
18trained personnel must submit to their school's administration
19proof of completion of a training curriculum to recognize and
20respond to an opioid overdose, which curriculum must meet the
21requirements of subsection (h-5) of this Section. Training must
22be completed annually. Trained personnel must also submit to
23the school's administration proof of cardiopulmonary
24resuscitation and automated external defibrillator
25certification. The school district, public school, or
26nonpublic school must maintain records relating to the training

 

 

10000SB2038sam001- 17 -LRB100 11368 MJP 22277 a

1curriculum and the trained personnel.
2    (h) A training curriculum to recognize and respond to
3anaphylaxis, including the administration of an undesignated
4epinephrine injector auto-injector, may be conducted online or
5in person.
6    Training shall include, but is not limited to:
7        (1) how to recognize signs and symptoms of an allergic
8    reaction, including anaphylaxis;
9        (2) how to administer an epinephrine injector
10    auto-injector; and
11        (3) a test demonstrating competency of the knowledge
12    required to recognize anaphylaxis and administer an
13    epinephrine injector auto-injector.
14    Training may also include, but is not limited to:
15        (A) a review of high-risk areas within a school and its
16    related facilities;
17        (B) steps to take to prevent exposure to allergens;
18        (C) emergency follow-up procedures;
19        (D) how to respond to a student with a known allergy,
20    as well as a student with a previously unknown allergy; and
21        (E) other criteria as determined in rules adopted
22    pursuant to this Section.
23    In consultation with statewide professional organizations
24representing physicians licensed to practice medicine in all of
25its branches, registered nurses, and school nurses, the State
26Board of Education shall make available resource materials

 

 

10000SB2038sam001- 18 -LRB100 11368 MJP 22277 a

1consistent with criteria in this subsection (h) for educating
2trained personnel to recognize and respond to anaphylaxis. The
3State Board may take into consideration the curriculum on this
4subject developed by other states, as well as any other
5curricular materials suggested by medical experts and other
6groups that work on life-threatening allergy issues. The State
7Board is not required to create new resource materials. The
8State Board shall make these resource materials available on
9its Internet website.
10    (h-5) A training curriculum to recognize and respond to an
11opioid overdose, including the administration of an opioid
12antagonist, may be conducted online or in person. The training
13must comply with any training requirements under Section 5-23
14of the Alcoholism and Other Drug Abuse and Dependency Act and
15the corresponding rules. It must include, but is not limited
16to:
17        (1) how to recognize symptoms of an opioid overdose;
18        (2) information on drug overdose prevention and
19    recognition;
20        (3) how to perform rescue breathing and resuscitation;
21        (4) how to respond to an emergency involving an opioid
22    overdose;
23        (5) opioid antagonist dosage and administration;
24        (6) the importance of calling 911;
25        (7) care for the overdose victim after administration
26    of the overdose antagonist;

 

 

10000SB2038sam001- 19 -LRB100 11368 MJP 22277 a

1        (8) a test demonstrating competency of the knowledge
2    required to recognize an opioid overdose and administer a
3    dose of an opioid antagonist; and
4        (9) other criteria as determined in rules adopted
5    pursuant to this Section.
6    (i) Within 3 days after the administration of an
7undesignated epinephrine injector auto-injector by a school
8nurse, trained personnel, or a student at a school or
9school-sponsored activity, the school must report to the State
10Board of Education in a form and manner prescribed by the State
11Board the following information:
12        (1) age and type of person receiving epinephrine
13    (student, staff, visitor);
14        (2) any previously known diagnosis of a severe allergy;
15        (3) trigger that precipitated allergic episode;
16        (4) location where symptoms developed;
17        (5) number of doses administered;
18        (6) type of person administering epinephrine (school
19    nurse, trained personnel, student); and
20        (7) any other information required by the State Board.
21    If a school district, public school, or nonpublic school
22maintains or has an independent contractor providing
23transportation to students who maintains a supply of
24undesignated epinephrine injectors auto-injectors, then the
25school district, public school, or nonpublic school must report
26that information to the State Board of Education upon adoption

 

 

10000SB2038sam001- 20 -LRB100 11368 MJP 22277 a

1or change of the policy of the school district, public school,
2nonpublic school, or independent contractor, in a manner as
3prescribed by the State Board. The report must include the
4number of undesignated epinephrine injectors auto-injectors in
5supply.
6    (i-5) Within 3 days after the administration of an opioid
7antagonist by a school nurse or trained personnel, the school
8must report to the State Board of Education, in a form and
9manner prescribed by the State Board, the following
10information:
11        (1) the age and type of person receiving the opioid
12    antagonist (student, staff, or visitor);
13        (2) the location where symptoms developed;
14        (3) the type of person administering the opioid
15    antagonist (school nurse or trained personnel); and
16        (4) any other information required by the State Board.
17    (j) By October 1, 2015 and every year thereafter, the State
18Board of Education shall submit a report to the General
19Assembly identifying the frequency and circumstances of
20epinephrine administration during the preceding academic year.
21Beginning with the 2017 report, the report shall also contain
22information on which school districts, public schools, and
23nonpublic schools maintain or have independent contractors
24providing transportation to students who maintain a supply of
25undesignated epinephrine injectors auto-injectors. This report
26shall be published on the State Board's Internet website on the

 

 

10000SB2038sam001- 21 -LRB100 11368 MJP 22277 a

1date the report is delivered to the General Assembly.
2    (j-5) Annually, each school district, public school,
3charter school, or nonpublic school shall request an asthma
4action plan from the parents or guardians of a pupil with
5asthma. If provided, the asthma action plan must be kept on
6file in the office of the school nurse or, in the absence of a
7school nurse, the school administrator. Copies of the asthma
8action plan may be distributed to appropriate school staff who
9interact with the pupil on a regular basis, and, if applicable,
10may be attached to the pupil's federal Section 504 plan or
11individualized education program plan.
12    (j-10) To assist schools with emergency response
13procedures for asthma, the State Board of Education, in
14consultation with statewide professional organizations with
15expertise in asthma management and a statewide organization
16representing school administrators, shall develop a model
17asthma episode emergency response protocol before September 1,
182016. Each school district, charter school, and nonpublic
19school shall adopt an asthma episode emergency response
20protocol before January 1, 2017 that includes all of the
21components of the State Board's model protocol.
22    (j-15) Every 2 years, school personnel who work with pupils
23shall complete an in-person or online training program on the
24management of asthma, the prevention of asthma symptoms, and
25emergency response in the school setting. In consultation with
26statewide professional organizations with expertise in asthma

 

 

10000SB2038sam001- 22 -LRB100 11368 MJP 22277 a

1management, the State Board of Education shall make available
2resource materials for educating school personnel about asthma
3and emergency response in the school setting.
4    (j-20) On or before October 1, 2016 and every year
5thereafter, the State Board of Education shall submit a report
6to the General Assembly and the Department of Public Health
7identifying the frequency and circumstances of opioid
8antagonist administration during the preceding academic year.
9This report shall be published on the State Board's Internet
10website on the date the report is delivered to the General
11Assembly.
12    (k) The State Board of Education may adopt rules necessary
13to implement this Section.
14    (l) Nothing in this Section shall limit the amount of
15epinephrine injectors auto-injectors that any type of school or
16student may carry or maintain a supply of.
17(Source: P.A. 98-795, eff. 8-1-14; 99-173, eff. 7-29-15;
1899-480, eff. 9-9-15; 99-642, eff. 7-28-16; 99-711, eff. 1-1-17;
1999-843, eff. 8-19-16; revised 9-8-16.)".